Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs

Molecular Cancer Research

Volumn 7, Issue 6, 2009, Pages 955-965

  Martin Fernandez, Cristina ^a   Bales, Juliana ^a   Hodgkinson, Cassandra ^a   Welman, Arkadiusz ^a   Welham, Melanie J ^b   Dive, Caroline ^a,c   Morrow, Christopher J ^a,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b University of Bath   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; DOXYCYCLINE; ETOPOSIDE; MUTANT PROTEIN; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN SUBUNIT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL LEVEL; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL GROWTH PROCESSES; CLONING, MOLECULAR; COLORECTAL NEOPLASMS; ENZYME INHIBITORS; ETOPOSIDE; FEMALE; HCT116 CELLS; HT29 CELLS; HUMANS; MICE; MUTATION; ORGANOPLATINUM COMPOUNDS; PROTEIN SUBUNITS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION;

EID: 67649592234     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0445     Document Type: Article

References (34)

1. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem 1998;67:481-507. (Pubitemid 28411136)
2. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501. (Pubitemid 37328931)
3. Huang CH, Mandelker D, Schmidt-Kittler O, et al. The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations. Science 2007;318:1744-1748 (Pubitemid 350274378)
4. Yu J, Zhang Y, McIlroy J, Rordorf-Nikolic T, Orr GA, Backer JM. Regulation of the p85/p110 phosphatidylinositol 3′-kinase: stabilization and inhibition of the p110α catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 1998;18:1379-1387 (Pubitemid 28100902)
5. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-1657 (Pubitemid 34579158)
6. Li J,Y en C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain,breast,and prostate cancer. Science 1997;275:1943-1947
7. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-362 (Pubitemid 27147102)
8. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554. (Pubitemid 38541907)
9. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-444 (Pubitemid 47123510)
10. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16. (Pubitemid 43199589)
11. 2-M delay. Clin Cancer Res 1997;3:1149-1156
12. Bain J,Plater L,Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007;408:297-315.
13. Liu Y, Shreder KR, Gai W, Corral S, Ferris DK, Rosenblum JS. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem Biol 2005;12:99-107. (Pubitemid 40118330)
14. Holleran JL, Egorin MJ, Zuhowski EG, Parise RA, Musser SM, Pan SS. Use of high-performance liquid chromatography to characterize the rapid decomposition of wortmannin in tissue culture media. Anal Biochem 2003;323:19-25. (Pubitemid 37393353)
15. Welman A, Cawthorne C, Barraclough J, et al. Construction and characterization of multiple human colon cancer cell lines for inducibly regulated gene expression. J Cell Biochem 2005;94:1148-1162 (Pubitemid 41420237)
16. Wang Q, Kim S, Wang X, Evers BM. Activation of NF-κB binding in HT-29 colon cancer cells by inhibition of phosphatidylinositol 3-kinase. Biochem Biophys Res Commun 2000;273:853-858 (Pubitemid 30481043)
17. Yeates LC, Gallegos A, Kozikowski AP, Powis G. Down-regulation of the expression of the p110, p85 and p55 subunits of phosphatidylinositol 3-kinase during colon cancer cell anchorage-independent growth. Anticancer Res 1999;19:4171-4176
18. Ikediobi ON, Davies H, Bignell G, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006;5:2606-2612. (Pubitemid 44848987)
19. Dijkers PF, Medema RH, Pals C, et al. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol 2000;20:9138-9148 (Pubitemid 32246103)
20. Morrow CJ,Gray A, Dive C. Comparison of phosphatidylinositol-3-kinase signaling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA. FEBS Lett 2005;579:5123-5128 (Pubitemid 41318079)
21. Samuels Y, Diaz LA, Jr., Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005;7:561-573 (Pubitemid 40799249)
22. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33:9-23. (Pubitemid 46137553)
23. William-Faltaos S, Rouillard D, Lechat P, Bastian G. Cell-cycle arrest by oxaliplatin on cancer cells. Fundam Clin Pharmacol 2007;21:165-172 (Pubitemid 46495937)
24. 1 CDKs in choroidal melanoma cells. FEBS Lett 1998;422:385-390
25. Raynaud FI, Eccles S, Clarke PA, et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007;67:5840-5850 (Pubitemid 46985018)
26. 1 arrest followed by cell death. Cancer Res 1999;59:5808-5814
27. Craddock BL, Orchiston EA, Hinton HJ, Welham MJ. Dissociation of apoptosis from proliferation, protein kinase B activation, and BAD phosphorylation in interleukin-3-mediated phosphoinositide 3-kinase signaling. J Biol Chem 1999;274:10633-10640 (Pubitemid 129518365)
28. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105. (Pubitemid 30781561)
29. Poh TW, Pervaiz S. LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway. Cancer Res 2005;65:6264-6274 (Pubitemid 40994412)
30. Gupta S,Ramjaun AR, Haiko P,et al. Binding of ras to phosphoinositide 3- kinase p110α is required for ras-driven tumorigenesis in mice. Cell 2007;129:957-968
31. Chang JG, Chen YJ,Perng LI,et al. Mutation analysis of the PTEN/MMAC1 gene in cancers of the digestive tract. Eur J Cancer 1999;35:647-651 (Pubitemid 29192976)
32. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-1068
33. Welman A, Barraclough J, Dive C. Generation of cells expressing improved doxycycline-regulated reverse transcriptional transactivator rtTA2S-M2. Nat Protoc 2006;1:803-811
34. Barraclough J, Hodgkinson C, Hogg A, Dive C, Welman A. Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells. Neoplasia 2007;9:745-754 (Pubitemid 47523236)